

CLINICAL TRIAL

CNGA3 - NCT02610582

Research



Safety and efficacy of a single subretinal injection of rAAV.hCNGA3 in patients with CNGA3-linked achromatopsia investigated in an exploratory, dose-escalation trial

Rare Eye Disease concerned by the trial :
CNGA3-linked achromatopsia

Status of the trial : active, not recruiting

Orphan drug recognition : Yes

Inclusion criteria : clinical diagnosis of achromatopsia, age ≥ 18 years, confirmed mutation in CNGA3, BCVA $\geq 20/400$; first cohort: BCVA $\leq 20/160$, area of residual outer nuclear layer thickness in OCT scans of posterior pole, ability to understand and willingness to consent to study protocol.

Exclusion criteria : [click here to see detailed criteria](#)



Inclusion opening date : 12/09/2014



Inclusion closing date : 22/09/2016

Children



Adults



Within ERN-EYE members



Principal location of the trial :

Center for Ophthalmic Research, University Hospital of Tübingen
Elfriede-Aulhorn-Str. 7
72076 Tübingen
Germany

[Contact details](#)



Principal investigator name :


Prof. Dr. Dr. Dominik Fischer



Other investigators :

Prof. Dr. med. Karl Ulrich Bartz-Schmidt
Katarina Stingl

University Hospital of Tübingen
Tübingen, Germany



Funder type : Other

[More informations](#)